Celiac Disease Pipeline Insight
DelveInsight’s, “Celiac Disease– Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Celiac Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Celiac Disease Understanding
Celiac Disease: Overview
Celiac disease is a chronic digestive disorder resulting from an immune reaction to gliadin, a gluten protein found in wheat, barley, rye, and sometimes oats. It involves inflammation and destruction of the inner lining of the small intestine and can lead to the malabsorption of minerals and nutrients.
Some common symptoms of celiac disease include:
- Gastrointestinal symptoms, such as abdominal cramps, diarrhea, gas, nausea and vomiting, and bloating
- Foul-smelling stools with excess fat in them
- Bone and joint pain
- Depression, irritability, and panic attacks
- Weakness and fatigue
- Easy bruising and nose bleeds
- Fluid retention
- Persistent hunger
- Iron deficiency anemia
- Malnutrition and nutrition deficiencies, including a lack of vitamin B12, D, and K
- Mouth sores and tooth discoloration
- Muscle wasting, muscle weakness, and muscle cramps
- Nerve damage, leading to tingling in the legs and feet
- Blood in the stools or in the urine
- Migraine headaches
Blood tests may detect:
- Antigliadin antibodies
- Endomysial antibodies
- Anti-tissue transglutaminase antibodies
Blood is screened for antibodies against deamidated gliadin peptide (TTG) and sometimes antigliadin (AGA) and andomysium antibodies (EmA). A small intestinal biopsy is considered the most accurate test for celiac disease. The doctor uses endoscopy to take samples of the intestinal lining. Usually, several samples are obtained to increase the accuracy of the diagnosis.
Doctors treat celiac disease by prescribing a gluten-free diet. Symptoms significantly improve for most people with celiac disease who follow a gluten-free diet. A dietitian can teach you how to avoid gluten while following a healthy and nutritious diet.
- The companies and academics are working to assess challenges and seek opportunities that could influence Celiac Disease R&D. The therapies under development are focused on novel approaches to treat/improve Celiac Disease.
- In October 2020, Building on its role as the nation's leading celiac disease patient advocacy organization and the largest nonprofit patient recruiter for celiac disease clinicatrials and studies, the Celiac Disease Foundation is pleased to announce its partnership with Provention Bio, Inc. (Nasdaq: PRVB), to provide clinical trial recruitment for the biopharmaceutical company's Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) Celiac Study testing the safety and effects of PRV-015 (an anti-interleukin-15 monoclonal antibody).
Celiac Disease Emerging Drugs Chapters
This segment of the Celiac Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Celiac Disease Emerging Drugs
Larazotide: Alba Therapeutics/Innovate Biopharmaceuticals
Larazotide (also known as AT-1001; formulated as the salt with acetic acid, larazotide acetate) is a synthetic eight amino acid peptide that functions as a tight junction regulator and reverses leaky junctions to their normally closed state. It is being studied in people with celiac disease.
AMG 714: Amgen
AMG 714 is a fully human monoclonal antibody, targeting interleukin-15 (IL-15), being developed by Celimmune, for the treatment of coeliac disease.
Further product details are provided in the report……..
Celiac Disease: Therapeutic Assessment
This segment of the report provides insights about the different Celiac Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Celiac Disease
There are approx. 25+ key companies which are developing the therapies for Celiac Disease. The companies which have their Celiac Disease drug candidates in the most advanced stage, i.e. phase III include, Alba Therapeutics/Innovate Biopharmaceuticals.
DelveInsight’s report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Celiac Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Celiac Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Celiac Disease drugs.
Celiac Disease Report Insights
- Celiac Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Celiac Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Celiac Disease drugs?
- How many Celiac Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Celiac Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Celiac Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Celiac Disease and their status?
- What are the key designations that have been granted to the emerging drugs?